Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

Dominick J. Angiolillo(University of Florida), Theodore A. Bass(Society for Cardiovascular Angiography and Interventions), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Francesco Franchi(Florida College), Andrew Darlington(University of Florida), Fabiana Rollini(Florida College), Brian A. Moser(Eli Lilly (United States)), Antonio Tello‐Montoliu(University of Florida), Masafumi Ueno(University of Florida), Luis A. Guzmán(University of Florida), Bhaloo Desai(University of Florida), Joseph A. Jakubowski(Indiana Biosciences Research Institute), José Luis Ferreiro(Institut d'Investigació Biomédica de Bellvitge)
Journal of the American College of Cardiology
September 1, 2014
10.1016/j.jacc.2014.06.1170
Cited by 181

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618